Celebrating Our Members
The Abbott ID NOW™ COVID-19 test brings rapid testing to the front lines on a portable instrument that can be deployed where testing is needed most.
It is the company’s second test to receive Emergency Use Authorization by the FDA for COVID-19 detection; combined, Abbott expects to produce about 5 million tests per month
Collaborating with select health authorities and institutions globally on clinical research related to COVID-19, AbbVie is supporting clinical studies and basic research, working closely with European health authorities and the U.S. Food and Drug Administration, Centers for Disease Control and Prevention, National Institutes of Health and Biomedical Advanced Research and Development Authority to coordinate on these efforts.
The Allergan Foundation Donates $2.0 Million to Community Organizations on Front-Line of COVID-19 Response
Amgen and the Amgen Foundation have committed up to $12.5 million to support COVID-19 relief efforts directly in the communities where team members live and work. The funds will be used to support emergency response efforts in Amgen’s U.S. and international communities, patient-focused organizations that are mounting their own response efforts, and international relief efforts by Direct Relief and International Medical Corps.
Amgen, is also partnering with Adaptive Biotechnologies Corp. in an effort to discover new drugs that can treat COVID19 with an unlikely hunter of antiviral treatments. The company, a pioneer of biotechnology, is best known for its drugs for cancer, with other products targeting high cholesterol, kidney disease and migraines.
BD and BioMedomics, a privately held, North Carolina-based clinical diagnostics company, announced the release of a new point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19 in as little as 15 minutes.
The development of vaccines will enable the immunization of a large part of the population. However, people who are particularly at risk of falling seriously ill or who have already been infected will need other treatment options. Therefore, we also need other approaches, such as antibodies that can neutralize the virus and small molecules to inhibit its replication, to fight the disease and save patients’ lives.
As the coronavirus (COVID-19) situation rapidly evolves, Bristol Myers Squibb is committed to taking every precaution to protect and support their global workforce and the communities where we live and work. In taking these actions, their priorities are to ensure the well-being of colleagues and to continue delivering the medicines our patients need through; Workplace and Community efforts, Supply of Medicines, Clinical Trials and Research, and Global Relief Efforts.
Even in the best of times, hundreds of thousands of Angelenos struggle to pay rent, put dinner on the table and take care of their health needs. Now, with COVID-19 (coronavirus) spreading across the Los Angeles region, Cedars-Sinai is stepping up assistance for populations that are vulnerable to the health and economic impacts of the virus.
Some people may face the loss of jobs and income due to the various precautions put in place to help slow the spread of COVID-19 Eli Lilly and Company is here to help anyone that may be struggling to afford their insulin. Call Eli Lilly at 833-808-1234 Monday through Friday from 8 a.m. – 8 p.m. ET.
To help you navigate through the COVID-19 crisis, here you’ll find the most relevant EY insights on structured crisis management, enterprise resilience and planning for recovery.
On March 12, 2020, Roche received FDA Emergency Use Authorization for the cobas® SARS-CoV-2 Test to detect the novel virus that causes COVID-19 disease. Hospitals and reference laboratories can run the test on Roche’s fully automated cobas® 6800 and cobas® 8800 Systems, which are widely available in the U.S. and around the world. Learn more here.
Gilead Sciences Statement on Positive Data Emerging From National Institute of Allergy and Infectious Diseases’ Study of Investigational Antiviral Remdesivir for COVID-19
Gilead Sciences. Inc. is aware of positive data emerging from the National Institute of Allergy and Infectious Diseases’ (NIAID) study of the investigational antiviral remdesivir for the treatment of COVID-19. We understand that the trial has met its primary endpoint and that NIAID will provide detailed information at an upcoming briefing.
Gilead is working closely with global health authorities to respond to the novel coronavirus (COVID-19) outbreak through the appropriate experimental use of the investigational compound remdesivir. Together with the U.S. Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (DHHS), National Institute of Allergies and Infectious Diseases (NIAID) and Department of Defense (DoD) – CBRN Medical; the China CDC and National Medical Product Administration (NMPA); the World Health Organization (WHO); and researchers and clinicians across Europe and Asia; Gilead is focused on contributing our antiviral expertise and resources to help patients and communities fighting COVID-19.
GSK is closely monitoring the COVID-19 pandemic and is supporting global efforts to tackle the virus. Since the outbreak, we have been actively exploring ways to help, with our science and expertise, alongside protecting the health and wellbeing of our people and managing our global supply chains to support patients and consumers who depend on our products.
With the rapid spread of coronavirus and increasing impact on clients, their people and operations, Hogan Lovells have mobilized a global team of cross-disciplinary lawyers to support you. Businesses are confronting risks to their employees and economic consequences. Hogan Lovells deep industry sector knowledge, combined with their legal and regulatory insights can help you to respond to both the immediate and longer term business risk stemming from the rapid, global spread of COVID-19.
StartX, a non-profit startup community of more than 1500 Stanford faculty and alumni founders, announces the launch of its StartX Med COVID-19 Task Force and the mobilization of its breakthrough medical companies providing solutions for the prevention, diagnostics and treatment of the novel coronavirus. The group of leading scientists, physicians and professor entrepreneurs will collaborate on outreach to government agencies, regulatory bodies and healthcare systems in the interest of public health.
Integral to their mission to improve human health, The Jackson Laboratory (JAX) is committed to helping address the coronavirus pandemic as rapidly as possible. Learn more about 1) How JAX is applying expertise in human genomics and mammalian genetics to help support the quickly evolving public health crisis. 2) The steps the Laboratory is taking to ensure the health of our employees, welfare of the mice under our care, and our mission of continuing to advance biomedical research during this difficult time.
Johnson & Johnson has been actively engaged in fighting pandemics for over a century. We have done it before, and we will do it again.
With our global reach comes a responsibility and unique ability to leverage our deep scientific expertise and extensive partnerships to take on this challenge. Our more than 130,000 employees around the world are mobilizing with urgency to address the critical needs of families, communities and healthcare providers around the world.
Our commitment to families around the world doesn’t change in a time of crisis: we’ll never stop taking care of you.
To help you understand your exposure to COVID-19, and more importantly, position your business to be resilient in the face of this and the next global threat, please review timely insights from KPMG business leaders.
Latham & Watkins have established a task force spanning multiple practices, who are serving as a central point for knowledge, learnings, and key insights from around the firm at this unprecedented time. Latham & Watkins have a robust technology infrastructure that enables our lawyers and professional staff to provide world class service to clients both in and out of the office. Their lawyers have had the option for remote working for many years and our professional staff have now been enabled to do the same.
Masimo announced that, in response to current worldwide blood shortages driven by the coronavirus pandemic, it is making rainbow® licenses available for no additional charge to hospitals where rainbow®-ready devices are already in use. The Masimo rainbow® platform allows for the noninvasive and continuous monitoring of 12 parameters, including hemoglobin (SpHb®), oxyhemoglobin (SpO2), and methemoglobin (SpMet®). Once rainbow® is enabled, hospitals can purchase RD rainbow® sensors at discounted prices during this pandemic. The program is available globally and is planned to continue until the pandemic subsides.
Medtronic continues to work hard to provide access to our life-saving medical technologies under these challenging circumstances. The impact of the COVID-19 pandemic on the patients we serve, the healthcare professionals with whom we work, and on our employees, is ever-changing. Communities across the globe are experiencing COVID-19 in different ways, requiring unique and localized responses.
Today, as the spread of COVID-19 disrupts life around the world, our ventilators, respiratory filters, oxygenation machines and pulse oximeters are being used by healthcare professionals on the front lines of this fight. These and other critical medical technologies are helping to sustain life for those patients with severe respiratory illness brought on by the virus. At the same time, we’re seeing a decrease and delay in certain elective medical procedures in affected countries around the world.
Around the world, Merck’s objectives remain the same: To protect the safety of our employees and to produce and supply our essential medicines and vaccines for those who need them. That is our unique responsibility as a company, and we factor that responsibility into every decision we make. Thanks to our colleagues, our manufacturing plants and clinical supply sites remain open around the world and, we are taking steps to make sure that continues to be the case. Our thoughts are with the people of all affected areas. We would also like to extend our sincere appreciation to the many health care providers and volunteers who are doing so much to help affected patients and communities.
Pfizer consistently and diligently monitors the supply of our medicines. We operate one of the most sophisticated supply chain systems in the industry, with over 40 Pfizer-owned sites and over 200 suppliers globally, which provides capacity and redundancy as needed.
Our manufacturing and supply chain professionals have been working non-stop to ensure that the global supply of Pfizer medicines continue to be available to patients. As of now, we have not seen a disruption in our supply chain, and all of our plants in impacted areas around the world are operational. We have implemented an unprecedented and comprehensive preparedness plan to control our site operations and will continue to provide timely updates if there is any new information to be shared.
On May 5th, Proteus Digital Health announced an outcomes-based initiative with the state of Tennessee’s Medicaid program, TennCare. The collaboration will support TennCare-covered patients undergoing Hepatitis C treatment and has the added benefit of assisting healthcare teams as they work to connect and monitor patients remotely during the pandemic. Under the contract, Proteus will only receive payment from TennCare if a patient on digital medicine therapy successfully completes treatment and is cured, with no additional cost to patients or providers.
Stanford Medicine scientists have launched dozens of research projects as part of the global response to COVID-19. Some aim to prevent, diagnose and treat the disease; others aim to understand how it spreads and how people’s immune systems respond to it.
Takeda initiating the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) to treat high-risk individuals with COVID-19, while also studying whether Takeda’s currently marketed and pipeline products may be effective treatments for infected patients. SARS-CoV-2 is the virus that causes COVID-19.
The COVID-19 pandemic presents unprecedented public health and economic challenges for global society. However, it also provides opportunities to show that new types of collaboration are not only possible, but that they can be implemented very quickly with the focused allocation of resources and expertise. In these uncertain times, prompt access to information is critical to the safety, efficiency and sustainability of the entire healthcare system. The volume of COVID-19 conversation, especially on Twitter, has exploded since the outbreak began, and it is critical for healthcare leaders to be able to cut through the noise, understand the landscape, and make informed decisions. We believe strongly that W2O has a role to play in meeting this need – by leveraging our technology-enabled analytics platform.
Contributing in the fight against the novel coronavirus, UC Davis Health researchers have two clinical trials underway for hospitalized patients with severe COVID-19.
The UC Davis School of Medicine is taking part in several studies on the safety and effectiveness of drugs against COVID-19. So far, Dr. Allison Brashear, dean of the School of Medicine, said it is too early to tell if the results are promising or not. But she said four COVID-19 patients are taking part in the study. The trials at the UC Davis Medical Center are part of two larger studies looking into two different drugs.
A proposal for human subjects research has been submitted to UC Irvine’s Institutional Review Board. If approval is granted, a notice will be posted at https://uci.edu/coronavirus/ in coming days.
“Then we hope that we’ll be able to test sera from people who would like to get their blood tested for coronavirus antibodies,” said Philip L. Felgner, director of UC Irvine’s Vaccine Research and Development Center and Protein Microarray Laboratory and Training Facility.
“This activity doesn’t require FDA approval. We need to anticipate more demand for this type of service,” he said.
UCLA Health is one of 75 sites around the globe participating in a clinical trial sponsored by the National Institutes of Health to test the effectiveness of a candidate antiviral drug against COVID-19.
The drug, called remdesivir, was originally developed as a treatment for Ebola. Although it was found to be safe, it was not effective in treating patients with the disease. In laboratory tests, however, it appears to work against the SARS-CoV-2 virus that causes COVID-19, which has raised hope that it may be effective against the coronavirus that has swept the globe, sickening and killing thousands.
The clinical trial was launched by the NIH’s National Institute of Allergy and Infectious Diseases.
Thousands of UCSF health care workers are mobilizing to prepare for the potential influx of patients sickened by COVID-19, even as hundreds of UCSF scientists race against time to defeat the deadly respiratory virus impacting communities around the world.
Heeding the order to shelter in place, UCSF has boosted telehealth portals to enable health care providers to see patients via phone and video; erected screening tents at UCSF Helen Diller Medical Center at Parnassus Heights and UCSF Medical Center at Mount Zion to cope with the expected surge in patients; and is now gearing up to test up to 1,000 people a day.
Engineers and doctors across the country are racing to build and fix ventilators as the number of people with COVID-19 climbs. That includes engineers from UC San Diego’s Jacobs School of Engineering and doctors from UC San Diego Medical Center. The testing is happening at a simulation lab on the UC San Diego campus. The facility is closed to outsiders, due to COVID-19 social distancing measures. But inside, one will find a team of doctors and engineers, equipped with personal protective gear, attaching ventilators to robotic lungs.
The University of California has been on the front lines in the fight against SARS-CoV-2, the virus that causes COVID-19, since the earliest indications of its emergence in China. From top-flight medical care to groundbreaking research, UC’s scientists and physicians across its 10 campuses and five academic medical centers are part of the global effort to treat, understand and ultimately defeat the virus.
Verily collaborates with CA Governor’s office, federal and local public health authorities on COVID-19
Verily, in collaboration with the California Governor’s office, federal, state and local public health authorities, will launch pilot intended to expand access to COVID-19 risk screening and testing for high risk individuals at Bay Area locations
The Vertex Foundation, a nonprofit charitable foundation, is making a $500,000 gift to Partners HealthCare, a Boston-based nonprofit hospital and physician network, to support the needs of patients and health care providers and bolster preparedness and response to the ongoing novel coronavirus (COVID-19) outbreak through enhanced testing capacity.